Insurgent Brands 2026 — Reference

Reading note on this list

Bain's "Insurgent Brands" is roughly defined as fast-growing US consumer brands over-indexing in growth versus the giant CPGs in their categories. Inclusion isn't a quality score — it's a velocity score. Some of these brands have strong long-term futures; some are riding a single narrative arc that will fade. I've tried to call out which is which.

For "primary lever," I've used four buckets:

• Distribution — they got into the right places (retail door count, marketplace shelf, hospitality) at the right moment.
• Quality — the product is meaningfully better than the legacy alternative on a single dimension a customer cares about.
• True Innovation — a real product or formulation breakthrough that didn't exist before.
• Story / Personality — the brand is carried by a founder, celebrity, or narrative more than the product per se.

Most winners have two of the four. I've named the dominant one. Where I'm uncertain about a logo, I've flagged it.

New Insurgents (2026 cohort)

Food & Beverage

Health, Beauty, Home

Existing Insurgents (returning brands)

These are brands Bain already had on the list and are still growing fast enough to retain their slot. Many are at $50M-$1B+ in revenue.

Food & Beverage

Health, Beauty, Personal Care, Home

Cross-brand strategic insights

Eight patterns jump out across the list. Some are well-known. A few are sharper than the conventional wisdom about insurgent brands.

1. Distribution is still the dominant lever, but it has bifurcated.

The biggest winners on this list got into the right physical shelf — Costco, Whole Foods, Target, Walmart — at the moment a category was opening up. Goose Creek, Bubble, Mando, Millie Moon, Magic Spoon, Chomps, OLIPOP, Liquid Death, Siete, Poppi all share this. The era of "DTC-only brands win" ended around 2021-2022. Every brand on this list at scale has cracked retail.

But there's a second distribution lane: the Amazon + influencer flywheel. Bloom, Physician's Choice, Force Factor, Guru Nanda, RYSE, and several supplement brands won mostly through Amazon SEO + creator content + value pricing. This is a different game from Whole Foods, but it's just as much a distribution play.

2. "Clean-label" alone is no longer the wedge.

Almost every brand on this list has clean ingredients, but only a handful win on clean ingredients alone. The winners pair clean with another differentiator: format (Liquid Death, Graza, Inaba, Mush, Solely), category creation (OLIPOP, Athletic Brewing, Magic Spoon, Mando), or radical transparency (LMNT, MALK).

3. Personality-led brands are over-represented but their half-life is short.

Lunchly, Garage Beer, Happy Dad, Bloom, lemme, Goodles, Black Rifle, Dan-O's, Once Upon a Farm — these are brands whose primary moat is a person. When the person's relevance fades or they move on, the brand's growth tends to plateau or reverse. Only a few personality-led brands transition into product-led brands successfully.

For Grow, this is relevant because Dan's story is genuinely compelling and underused. But you should be careful not to only be that story — the product needs to be able to walk on its own legs the day a new owner takes over.

4. The "format is the product" pattern is the most defensible new-brand wedge.

Liquid Death (cans), Graza (squeeze bottle), OLIPOP (functional soda), Inaba (lickable purée), Solely (single-ingredient gummy), Mush (refrigerated oats), Force of Nature (electrolysis device), Vejo (pod blender), Goose Creek (mass-priced candle), Mando (whole-body deodorant) — all of these brands' moats live in the format, not the brand or the ingredients. Format moats are harder to copy than recipes.

5. The exit market is paying $1B+ for clean-label, founder-led brands with $50M-$200M revenue.

In the last 24 months: Poppi → PepsiCo for $1.95B, Siete → PepsiCo for $1.2B, Dr. Squatch → Unilever for ~$1.5B. Earlier comps: Native → P&G ~$100M. Mando is built by the Native team and is widely expected to be the next P&G acquisition.

The pattern: revenue $50M-$300M, contribution margin healthy, brand has a clear retail beachhead AND a story a Big CPG can lift onto a global stage. None of these acquirers care about a $5M brand. They start paying real money around $50M revenue.

6. The "Big CPG can't make this in their labs" test predicts the exits.

Every big exit on this list — Poppi, Siete, Dr. Squatch, Mando (likely next), Liquid Death (eventual) — is something the acquirer's R&D would not have invented. The acquirer paid for the brand and category position, not the formulation.

For Grow, the answer is yes on both axes: the formulation moat (plant-based fragrance at synthetic performance levels), and customer trust (chemical-sensitive customers will not be tricked by a Big CPG product).

7. Wholesale matters, but in a specific way.

The brands here that scaled into Whole Foods, Target, Costco, Walmart did it by treating wholesale as a trust-transfer mechanism, not a margin trade. The retailer's reputation lent credibility to the brand. The brand's social presence drove velocity that protected the slot.

8. "Boring categories made interesting" is the new fertile ground.

Olive oil (Graza), water (Liquid Death), cottage cheese (Good Culture), pancake mix (Kodiak), seasoning (Dan-O's), tampons (CORA), pimple patches (Starface), lip balm (eos), wipes (Dude / Goodwipes), formula (Bobbie / Kendamil / By Heart), bone broth (Kettle & Fire), seaweed snacks (Gimme).

Notice what's missing: there's not a single ground-breaking technology brand on this list. The Insurgent Brands list is dominated by commodity categories that someone made interesting again — through packaging, format, founder voice, or category-creation framing.

What Grow can learn — concretely

These map to the existing strategy docs (Relaunch Plan moves, Exposure Playbook pillars). I've called out where each lesson reinforces, contradicts, or extends what's already on the page.

A. The diffuser launch should be positioned as a category-creation play, not a SKU launch.

The pattern across Liquid Death, OLIPOP, Athletic Brewing, Mando is that they didn't launch a product — they renamed the category. Liquid Death is "death to plastic" not "another mineral water." OLIPOP is "modern soda," not "another kombucha." Mando is "whole-body deodorant," not "another Native variant."

Grow has a similar move available: the diffuser isn't "a nebulizer for plant-based oils." It's the first home fragrance system that performs like a synthetic, made entirely from plants. Or, framed as a category: "Real Fragrance" as opposed to Synthetic Fragrance — where Grow defines the category at launch.

B. Premiumization must come with a packaging upgrade, not just a price tag.

The lesson from Graza, MALK, MONDAY, Kit·sch, Bubble: at clean-label premium price points, packaging that signals premium is non-negotiable. Plastic spray bottles at $22 will face customer resentment that doesn't exist at $16.

C. "Story" is necessary, but Grow needs the Dan-as-founder story to scale 5x harder than it currently does.

The brands with personality engines (Dr. Squatch, Liquid Death, Built Bar, Magic Spoon) all spend disproportionately on founder voice + brand-personality content. Grow's founder story is genuinely compelling and underused relative to the Bain list comparables.

Most comparable brands had 50-200 founder-led short-form videos in their first growth year. Pillar 1 of the Exposure Playbook should be 2-3x more aggressive than currently scoped.

D. Retention is a feature of these brands, not the engine.

None of the exit-comparable brands (Poppi, Siete, Dr. Squatch, Mando) won on retention. They won on rapid first-trial-to-mass-awareness conversion. Their retention is good but not exceptional.

E. The wholesale path has more 2026 leverage than the Relaunch Plan currently assumes.

Mando, Goose Creek, Millie Moon, Bubble, Odele — all of these brands' inflection point was a single anchor retailer. The retail anchor was disproportionately responsible for the brand's growth velocity.

The Relaunch Plan correctly puts wholesale in "the longer game" with no 2026 revenue commitment. The Insurgent Brands list suggests this is too conservative. A single right anchor retailer in 2026 could be more revenue-significant than Move 4. Whitney's pipeline should be evaluated for one breakout door, not 150 average doors.

F. The Klaviyo playbook is right, but the email content has to rise to the level of these brands' brand voice.

Liquid Death's emails are funny enough to forward. Dr. Squatch's emails read like Dr. Squatch's YouTube ads. Magic Spoon's emails feel like Magic Spoon's brand. The retention engine in the Bain list is brand-voice-as-retention, not "more A/B tested emails."

If a customer can't tell a Grow email from a Yankee Candle email, the retention work isn't done.

G. The "boring category made interesting" frame is the most underused asset Grow has.

The competitive set is not Le Labo or Aesop. The competitive set is the chemical-laden mass aisle, and that aisle has been waiting for a clean-label disruptor for 20 years.

Long-term strategy scaffold (Part I version — superseded by Part III)

What's missing — open questions for the Playbook

Things this analysis cannot answer without more input from Dan:

1. Path commitment — Lifestyle vs. Accelerated Exit vs. Professional Management. Pick one or commit to a decision date.
2. Diffuser pricing and positioning — "natural answer to Le Labo" (premium indie) or "natural answer to Glade / Febreze" (mass clean)? Different brands.
3. Wholesale anchor — One hero retailer in 2026, or 150 average doors? Math differs by 5-10x.
4. Founder cadence — willing to commit to 100+ pieces of founder-led content in 2026?
5. Capital posture — self-funded → break-even → reinvest? Or raise growth equity at the 2027 inflection?
6. Real Strategic Playbook 2026 doc — Suggest consolidating into a canonical Grow_Strategic_Playbook_2026_v2.md.

What the Playbook actually says

The Strategic Playbook is a 12-part, ~1,000-line synthesis of 200+ strategic notes. The most decision-relevant content:

The 2030 Vision (concrete numbers Dan committed to)

• Revenue $20M, EBITDA $5M (25% margin), exit at 15x = $75M sale price.
• 2026 milestone: $5M revenue, 20% MER, 40% COGS, 20% G&A, 20% profit. Break-even by year-end.
• Growth rate: 42% annually (double every 2 years) — explicitly chosen as the lower growth target in exchange for profitability.

The dominant positioning

"Painkiller, not vitamin." The line is "You love fragrance. But it's not safe. Grow is." — clean fragrance as the safe alternative to toxic mass-market product. Not luxury, not wellness-curious — safety-driven clean.

The product strategy

Diffuser is the explicit 2026 anchor. Three phases — foundation (Q1: 2-3 SKU launch, $40-80 pricing), innovation (Q2-Q3: smart diffuser with app, "cocktail mixing" layered scents, subscription), ecosystem (Q4: bundles, cross-sell, wholesale test). Streamline the spray catalog to top 20% of SKUs.

The "little channels" thesis

• Don't become proficient in paid media.
• Focus on small, asymmetric channels big competitors can't copy.
• Build owned acquisition (email, GPT, community).
• Reduce paid-media dependency post break-even.

Viral GPT for Fragrance Discovery — the boldest move in the Playbook

Build a custom GPT that helps customers find their perfect fragrance via personality quiz + AI recommendations. Captures zero-party data, creates a viral shareable experience, lowers CAC through organic sharing. Named partner: Prashun for AI custom fragrance technology.

The team / lifestyle vision

• Max 50 people + warehouse.
• Founder works with max 7 direct reports.
• Founder transitions to Executive Chair role post break-even.
• 20% profit-sharing pool to staff (converts to 20% ownership in a sale event).

Exit paths (as named in the Playbook)

• Path A — Lifestyle Business. "Grow is not a rush & sell company. It's boutique." Inspirations: Rolex, Augusta, Lego.
• Path B — Accelerated Exit. Break-even-type deal to a strategic buyer.
• Path C — Professional Management. Install CEO, transition to Exec Chair, build to a larger exit on a longer timeline.

Named external network

Jake (coaching), John Replogle / 1BV (recruiting brand, media, potential buyer network), Mike H (ICP), Glen (legal, stock structure, exit), Nikita (financial modeling).

Where Part I was directionally right

Most of the Insurgent Brands lessons in Part I survive the reconciliation:

• "Format is the product" as the most defensible new-brand wedge. The Playbook's diffuser strategy (and the "cocktail mixing" sub-concept) is exactly this.
• Aluminum bottles / packaging upgrade at premium price points. Reinforced by the Playbook's "premium quality without luxury pricing" framing.
• Founder-led content cadence at 2-3x current scale. Consistent with the Playbook's emphasis on Dan's origin story.
• Wholesale anchor — one hero retailer over 150 average doors. Consistent with the Playbook's wholesale test in Phase 3.
• Brand voice in retention / email. Consistent with email-as-primary-retention-channel emphasis.

Where Part I needs to be revised against the Playbook

1. Acquirer landscape and dollar targets

Part I implied Grow needed to reach $50M-$300M to be acquirable, citing Poppi ($1.95B), Siete ($1.2B), Dr. Squatch ($1.5B). The Playbook's stated target is $20M revenue / $5M EBITDA / $75M sale price at 15x — a smaller, more realistic target with a different acquirer set. See Part III for the revised dual-path framework.

2. The "painkiller positioning" reframes the brand-voice question

Part I suggested "Grow is the OLIPOP / Liquid Death / Mando of home fragrance." That's directionally right but the Playbook is sharper: Grow is the safety brand for people who love fragrance but don't trust what's in conventional products. The closest analogs aren't Liquid Death or Mando — they're CORA, By Heart, Bobbie, Vanicream, Blue Lizard, Force of Nature.

This changes the brand voice meaningfully. Painkiller voice is more clinical, more transparent, more direct than the irreverent voice that powers Liquid Death and Dr. Squatch.

3. The Viral GPT was missing from my analysis entirely

None of the Insurgent Brands on the Bain list have built a Viral GPT discovery tool — most still use traditional product quizzes. Grow's Viral GPT, if executed, would be a genuinely novel acquisition mechanic that no comparable brand has. This is the highest-leverage idea in the entire Playbook for "little channels" thinking.

The Viral GPT isn't a marketing feature. It's a customer-acquisition product. Built well, it could replace 30-50% of Meta spend for new-customer acquisition by Q4 2026. Built poorly, it's a website widget. Execution gating question: has Prashun started? What's the spec? Does the team have bandwidth on top of the diffuser launch and Email Retention Project?

4. The 42% growth + 20% profit framing supersedes the "exposure / volume growth" framing

The Exposure Playbook (April 2026) implicitly assumes growth is the binding constraint. The Strategic Playbook (October 2025) explicitly makes profitability the binding constraint, with growth subordinated. These are different operating philosophies and they conflict in places.

Reconciliation: from the six Exposure Playbook pillars, the most consistent with the Strategic Playbook's vision are:

• Pillar 1 (Podcast Guesting) — pure founder voice, zero cost. Stays.
• Pillar 2 (AI Discovery / LLMO) — extends naturally into the Viral GPT. Combine into one workstream.
• Pillar 3 (E-Commerce Wholesale) — only if it's one hero retailer, not 150 small accounts. Modify.
• Pillars 4-8 should be deferred to 2027+ unless they directly compound with the diffuser launch.

5. The Executive Chair / lifestyle endpoint changes the urgency calculus

Part I framed long-term in terms of "compete for an insurgent-brand exit at $300M-$1B." The Playbook is explicit: Dan does not necessarily want a rush-and-sell company. "Take inspiration from Rolex, Augusta, Lego — private, long term." The exit is one option among three.

Several Part I aggressions should be moderated:

• Exit timing: if Lifestyle is preferred, the timing question goes away. The first decision is which path, not when to exit.
• Capital posture: default assumption should be no outside capital unless and until an Accelerated Exit becomes the explicit choice.
• Profit-sharing structure (20%-to-staff): needs Glen review for cap-table implications before any equity grants are issued.

How the Bain Insurgent Brands list reads through the Playbook lens

With the Playbook in hand, here's the sharper read of which brands are actually relevant analogs for Grow's stated trajectory:

Most relevant ($30-150M exits, painkiller positioning, founder-led)

• CORA — clean tampons, Target-anchored, painkiller positioning, exited to Edgewell ~$80M. Closest direct analog for Grow's likely path.
• Force of Nature — clean home cleaning, painkiller positioning, hardware-software-consumable model. Path-A analog.
• By Heart / Bobbie / Kendamil — clean infant formula, painkiller positioning. All in the $30-150M revenue band.
• Blue Lizard — mineral sunscreen, painkiller positioning. Acquired by Crown Laboratories in 2017.
• Vanicream — sensitive-skin moisturizer, won by being trusted in a category customers don't trust generally.
• Native (referenced via Mando) — clean deodorant, painkiller positioning, sold to P&G ~$100M.

Less relevant (different positioning)

• Liquid Death, Dr. Squatch — irreverent brand voice, not painkiller.
• Poppi, Siete, OLIPOP — category-creation plays, not painkiller. Bigger exits, longer build, more capital-intensive.
• Lunchly, Garage Beer, Happy Dad, Bloom — personality-led with shorter half-life.

What the Playbook is missing or out of date

Reading the Playbook against current operational reality (the Relaunch Plan, the Turnaround Red Team, the Canopy 90-day, the Email Retention project), several gaps stand out — places where the October 2025 plan needs a refresh against April-May 2026 data:

1. 2026 financial targets are aspirational vs. actual run rate. Playbook says $5M revenue, 20% MER, 20% profit. Q1 2026 actuals: $3.4M trailing, MER ~28%, $642K loss in 2025. The Relaunch Plan's $4.2M-$4.8M is the realistic 2026 range. The Playbook's $5M target should be reframed as 2027-aspirational, not 2026.
2. The Playbook predates the Q1 acquisition crisis. New-customer share fell from 51% (Q1 2025) to 24% (April 2026 partial). The "little channels" framing is right but the urgency of fixing the top-of-funnel — Move 1 of the Relaunch Plan — isn't reflected in the Playbook.
3. The Playbook predates Canopy. The Canopy 90-day assessment recommends "lean no on renewal." The Playbook's "Performance Marketing Lead hire" should be updated against the current Mike Hourigan re-engagement decision. This is a 2-week decision window, not a 2026 hire.
4. The Viral GPT is named but not specced. "Prashun?" appears with a question mark in the Playbook. Six months later, no spec, no scope, no timeline. If this is the highest-leverage acquisition idea, it deserves a 2-page spec by end of May.
5. Diffuser pricing has evolved. Playbook says $40-80; Relaunch Plan says $100+ with refill subscription. Confirm and reconcile.
6. Decile app for segmentation predates the Klaviyo retention build-out. Klaviyo segments + the Datahub's dim_customers table + Dave's repeat-rate cohorts may obviate Decile. Reconfirm.
7. The Playbook's hiring ambition (5-6 hires) conflicts with Move 5 of the Relaunch Plan (hold overhead at $1M). One of these is wrong, and it's probably the Playbook — written six months ago in a different financial reality.

The exit option set, ordered by Dan's stated preference

The full menu of plausible exits for an $8M-$30M revenue clean-fragrance brand at the 2028-2030 horizon:

Path 1 — Strategic fold-in (the "Edgewell / Native model")

A category-adjacent CPG with established retail distribution and supply chain buys Grow because they can't build it. Grow plugs a clean-label gap in their portfolio. They lift Grow's brand into their existing distribution and manufacturing scale. The exit is a multiple of EBITDA or revenue.

Realistic acquirer set at the $75M-$200M tier

Strategic pricing dynamics: Strategic fold-ins typically pay 2-4x revenue or 10-15x EBITDA. At the Playbook's $20M revenue / $5M EBITDA, that's a $40M-$80M strategic deal — comfortably eight figures. If Grow grows past $30M revenue with healthy EBITDA, the upper end reaches $100M-$150M.

Path 2 — Family office / permanent-capital holding co (the "Rolex / Augusta / Lego model")

A family office (single-family or multi-family), a HoldCo built on family money, or a permanent-capital vehicle buys Grow as a long-term hold — not a 5-year flip. The buyer cares about cash generation and brand durability, not growth-at-all-costs. Dan stays on as CEO or transitions to Exec Chair on his own timeline. The deal often includes seller financing, equity rollovers, or earn-outs that align long-term.

Realistic family-office / HoldCo set at the $20M-$80M tier

Family office pricing dynamics: Family offices typically pay slightly lower headline multiples than strategics (8-12x EBITDA vs. 10-15x) but offer better deal terms — equity rollover, seller financing, founder optionality, no aggressive earn-out pressure. Total economic value to Dan can be similar or better, especially with a meaningful equity rollover.

How the parallel paths coexist operationally

The two paths sound different but require building almost identical traits. That's the strategic insight: Dan doesn't have to choose between them in 2026 or 2027. He optimizes for both, and either becomes a real option at the 2028-2030 inflection.

Mapping back to the Playbook's three paths

The Playbook (October 2025) named three paths: Lifestyle Business, Accelerated Exit, Professional Management. Mapping:

• Playbook "Lifestyle Business" = Path 3 (Independent / "no exit"). Always preserved.
• Playbook "Accelerated Exit" = Path 1 (Strategic fold-in). Promoted to first-tier.
• Playbook "Professional Management" = a posture for the founder, not an exit type. Can apply to Path 1, Path 2, or Path 3. The decision to install a CEO and transition to Exec Chair is independent of which exit path is chosen.

Refined "traits to build" prioritization

Working from the dual-path framework, here's a refinement of Part I's eight traits — by priority for Dan's preferred paths:

Tier 1 — matters most for both Path 1 and Path 2

1. Profitability + clean financials — both paths require it. Break-even by EOY 2026 is the foundation.
2. Defensible category position — both want category leadership in clean home fragrance. The diffuser launch and the "real fragrance" positioning are the work.
3. Refill subscription / recurring revenue — both paths value it; family offices weight it disproportionately.
4. Brand voice that matches "painkiller, not vitamin" — necessary to read as durable, not faddy.

Tier 2 — matters more for Path 1, still useful for Path 2

5. Hero retail anchor — proves category leadership; less essential for family office but still positive.
6. Multi-platform media engine — proves the brand can operate without founder dependency.
7. Founder cadence on content — required through close and 12-24 months after.

Tier 3 — Path 2 specifically values

8. Operator team that can run without Dan — permanent-capital partners want this so the brand keeps compounding regardless of founder presence. For Path 2, building Whitney / Katelyn / Nikita into clear domain leaders is part of the exit asset.
9. Founder optionality / extended runway — family-office deals often include "Dan stays as CEO 3-5 years, then transitions" rather than "Dan signs an earn-out and leaves."

Tier 4 — PE-only (deprioritized)

10. Aggressive growth narrative — only matters for PE.
11. Recapital story — only matters for PE.

Implications for 2026-2027 execution

If Paths 1 and 2 are co-primary, several near-term decisions sharpen:

1. Outside capital posture: default to no. Both paths are exit paths, not growth-equity paths. Raising growth capital in 2027 would dilute Dan's eventual take from either path and create pressure to chase PE-style growth. Stay self-funded through break-even. The only exception: a small family-office minority investment that pre-positions Path 2.
2. Network priority for John Replogle conversations: two parallel ask-pipelines. (a) Clean-label CPG strategic relationships — Edgewell, Helen of Troy, SC Johnson Lifestyle Brands at the top. (b) Family-office and permanent-capital introductions — Permanent Equity / HoldCo operators and direct family-office consumer-brand investors. John should know we're optimizing for both, not picking one.
3. Profit-sharing / equity-grant structure (the 20%-to-staff plan) needs Path-2 review with Glen. Family offices are often more sensitive to equity-grant structure than strategics. If 20% of equity is committed to staff, the family-office buyer is buying 80%. The structure has to be clean, vested, and well-documented before any conversation. Glen review before any equity grants is now a Tier-1 item.
4. Operator-team build-out matters more under Path 2. A family-office buyer who wants Dan to stay 3-5 years still wants confidence the team can execute without him after. Whitney as wholesale lead, Katelyn as marketing / brand voice lead, Nikita as CFO-equivalent, and a Performance Marketing Lead hire are all "exit assets" under Path 2 — not just operating hires.
5. Audit prep should start in 2027, not 2029. Both paths require audited (not just reviewed) financials. The Datahub work + Nikita's QB sub-account work is the foundation. Adding a low-cost annual audit by Q4 2027 makes both paths cleanly executable in 2028.
6. The "no rush, no sell" floor stays preserved. Path 3 (Independent) is the always-available baseline. The whole point of building toward Paths 1 and 2 in parallel is that Dan keeps optionality — including the option to do neither and keep running the business as a profitable lifestyle company indefinitely.

Open questions for the Playbook v2 consolidation

1. Confirm the dual-path framing is right. Are Paths 1 + 2 + 3 the intended menu, with Paths 4-8 as awareness-only?
2. Glen conversation on Path-2 implications for the 20%-to-staff equity-grant plan — family-office buyers' typical preferences on staff equity vs. profit-share-only structures.
3. John Replogle conversation: the two parallel ask-pipelines. What's his current network depth in family-office / HoldCo consumer-brand territory vs. clean-label CPG strategic territory?
4. Permanent Equity / HoldCo operator outreach: who's the right first introduction? Mark Brooks at Permanent Equity is the obvious test case.
5. The "founder stays 3-5 years post-sale" version of Path 2 needs Dan's gut check. Is the longer founder commitment a feature or a bug, given the Exec Chair preference?